home / stock / tnya / tnya quote
Last: | $4.20 |
---|---|
Change Percent: | -1.34% |
Open: | $4.54 |
Close: | $4.20 |
High: | $4.54 |
Low: | $4.14 |
Volume: | 179,516 |
Last Trade Date Time: | 05/10/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.2 | $4.54 | $4.2 | $4.54 | $4.14 | 179,516 | 05-10-2024 |
$4.48 | $4.47 | $4.48 | $4.63 | $4.402 | 291,461 | 05-09-2024 |
$4.51 | $4.6 | $4.51 | $4.6 | $4.49 | 164,580 | 05-08-2024 |
$4.61 | $4.54 | $4.61 | $4.72 | $4.4704 | 398,948 | 05-07-2024 |
$4.54 | $4.76 | $4.54 | $4.89 | $4.5 | 235,331 | 05-06-2024 |
$4.68 | $4.72 | $4.68 | $4.96 | $4.59 | 91,741 | 05-03-2024 |
$4.62 | $4.79 | $4.62 | $4.8 | $4.59 | 156,859 | 05-02-2024 |
$4.68 | $4.58 | $4.68 | $4.81 | $4.47 | 155,289 | 05-01-2024 |
$4.54 | $4.51 | $4.54 | $4.64 | $4.45 | 171,204 | 04-30-2024 |
$4.54 | $4.31 | $4.54 | $4.64 | $4.31 | 157,709 | 04-29-2024 |
$4.31 | $4.25 | $4.31 | $4.36 | $4.2224 | 100,974 | 04-26-2024 |
$4.22 | $4.25 | $4.22 | $4.3 | $3.97 | 384,566 | 04-25-2024 |
$4.38 | $4.45 | $4.38 | $4.515 | $4.31 | 321,384 | 04-24-2024 |
$4.45 | $4.43 | $4.45 | $4.69 | $4.43 | 145,054 | 04-23-2024 |
$4.43 | $4.33 | $4.43 | $4.5141 | $4.26 | 296,657 | 04-22-2024 |
$4.32 | $4.24 | $4.32 | $4.378 | $4.1501 | 409,291 | 04-19-2024 |
$4.29 | $4.29 | $4.29 | $4.4 | $4.14 | 288,192 | 04-18-2024 |
$4.3 | $4.54 | $4.3 | $4.54 | $4.25 | 260,747 | 04-17-2024 |
$4.46 | $4.38 | $4.46 | $4.53 | $4.3605 | 181,550 | 04-16-2024 |
$4.47 | $4.5 | $4.47 | $4.66 | $4.4 | 284,095 | 04-15-2024 |
News, Short Squeeze, Breakout and More Instantly...
Tenaya Therapeutics Inc. Company Name:
TNYA Stock Symbol:
NASDAQ Market:
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company wi...
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that i...
Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of 2024 On Track to Dose First Patient in RIDGE™-1Phase 1b Clinical Trial of TN-401 for PKP2-associated ARVC in Second Half 2024 $47 Million Net Proceeds from R...